Sector News

Alexion appoints Deborah Dunsire, M.D. to Board

January 23, 2018
Life sciences

Alexion Pharmaceuticals, Inc. today announced that Deborah Dunsire, M.D. has been appointed to the Company’s Board of Directors as a new independent director.

Dr. Dunsire is a proven leader in the biopharmaceutical industry with three decades of experience and a successful track record of growing businesses, fostering R&D and commercial development, and creating shareholder value.

Dr. Dunsire served as President and Chief Executive Officer of Millennium Pharmaceuticals, Inc. from 2005-2013, where she led the transformation of the company into a biotechnology industry leader. Prior to Millennium, which became Takeda Oncology, Dr. Dunsire led the Novartis North America Oncology Business, which during her ten-year tenure grew in revenues from $50 million to more than $2.2 billion, and she served for eight years with Sandoz AG. Dr. Dunsire currently serves as President and Chief Executive Officer of Xtuit Pharmaceuticals, Inc., a privately held biopharmaceutical company developing novel therapeutics. Dr. Dunsire also serves on the boards of Xtuit and Ultragenyx Pharmaceutical, Inc., and previously served on the boards of Takeda Pharmaceuticals, Allergan, Inc. and FORUM Pharmaceuticals, Inc. She received her medical degree from the University of Witwatersrand, Johannesburg, South Africa.

David Brennan, Chairman of the Board, commented, “We are delighted to welcome Deborah to Alexion’s Board of Directors. Her experience will be highly valuable to our board as we continue to position Alexion to deliver long-term growth and sustainable value for our shareholders. Alexion has made excellent progress over the past year, enhancing our corporate governance, refocusing our business strategy and achieving important corporate milestones. We look forward to working with Deborah as we continue to build on our leadership in treating patients with rare diseases.”

Dr. Dunsire added: “Alexion is a world-class organization with innovative therapies and proven leadership in treating patients with rare diseases. I am excited to join the Alexion Board and look forward to contributing to the Company’s continued success.”

“Elliott strongly supports Deborah’s appointment to the Alexion Board,” said an Elliott spokesperson. “She is one of the biopharmaceutical industry’s most respected leaders and brings significant experience to the Board. This is another welcome step by Alexion to build on its recent accomplishments and enhance value creation for all shareholders.”

Source: Alexion

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).